Clinical trials: Graft-vs-host Disease
Hematologic Malignancies
Efficacy Study of a TXA127 to Reduce Acute Graft-vs-Host Disease in Subjects Undergoing Double Umbilical Cord Blood Transplantation
The purpose of this study is to evaluate the efficacy of TXA127 to reduce the incidence (Grade II-IV) of acute Graft-vs.-Host Disease (aGVHD) in adult subjects undergoing double umbilical cord blood transplantation (UCBT).
- Trial name
- NCT01882374
- Testing
- TXA127
- Where
- United States
- Sponsor
- Tarix Pharmaceuticals
Graft Versus Host Disease, Leukemia
Clofarabine, Melphalan, and Thiotepa Followed By a Donor Stem Cell Transplant in Treating Patients With High-Risk and/or Advanced Hematologic Cancer or Other Disease
RATIONALE: Giving chemotherapy, such as clofarabine, melphalan, and thiotepa, before a donor stem cell transplant helps stop the growth of cancer or abnormal cells.
- Conditions
- Graft Versus Host Disease, Leukemia, Myelodysplastic Syndromes
- Trial name
- NCT00423514
- Testing
- filgrastim, clofarabine, melphalan
- Where
- United States
- Volunteers
- 38 people
- Sponsor
- Memorial Sloan Kettering Cancer Center
Graft vs. Host Disease
Obinutuzumab in cGVHD After Allogeneic Peripheral Blood Stem Cell Transplantation
This research study is studying a drug called obinutuzumab as a means of preventing chronic Graft vs. Host Disease (cGVHD).
- Trial name
- NCT02867384
- Testing
- Obinutuzumab
- Where
- 5 sites in United States
- Volunteers
- 181 people
- Sponsor
- Dana-Farber Cancer Institute
Graft Versus Host Disease
Dendritic Cells in Patients Following Allogeneic Hematopoietic Stem Cell Transplantation
We plan to investigate prospectively and simultaneously skin and blood DC subtypes, their donor/recipient origin and the correlation of DC reconstitution kinetics with treatment, clinical outcome and incidence of aGvHD in…
- Trial name
- DCalloTX (NCT00450268)
- Testing
- blood draw, skin shave biopsy
- Where
- Germany
- Volunteers
- 50 people
- Sponsor
- Technische Universität Dresden
Periodontal Diseases, Periodontitis
HALP Score, Blood-Based Inflammatory Indices, and Salivary MMP-8 in Periodontal Disease and Healing After Non-Surgical Therapy
This observational clinical study aims to investigate the relationship between the HALP score (Hemoglobin × Albumin × Lymphocyte / Platelet), several blood-based inflammatory indices (including NLR, PLR, LMR, and SII), and…
- Conditions
- Periodontal Diseases, Periodontitis, Gingivitis; Chronic
- Trial name
- NCT07312045
- Testing
- Non-surgical Periodontal Therapy
- Where
- Turkey (Türkiye)
- Volunteers
- 180 people, healthy volunteers welcome
- Sponsor
- Ömer Faruk Okumuş
Acute Graft Versus Host Disease
Safety and Clinical Activity of Itolizumab in aGVHD
To evaluate the safety, tolerability, PK, PD, and clinical activity of Itolizumab in subjects with Newly diagnosed Acute Graft Versus Host Disease(aGVHD).
- Trial name
- NCT05823675
- Testing
- Itolizumab, Methylprednisolone
- Where
- China
- Volunteers
- 44 people
- Sponsor
- Biotech Pharmaceutical Co., Ltd.
Mountain Sickness, Chronic
Chronic Mountain Sickness, Systemic Vascular Function
Diseases associated with chronic hypoxemia like chronic obstructive pulmonary disease (COPD) or emphysema, represent major medical and socio-economical problems and one of the leading cause of morbidity and mortality in the…
- Trial name
- CMS (NCT01182792)
- Testing
- Vitamin C and E
- Where
- 2 sites in Bolivia, Switzerland
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- University of Lausanne Hospitals
Multiple Myeloma
A Study of KW-2478 in Combination With Bortezomib in Subjects With Relapsed and/or Refractory Multiple Myeloma
The purpose of this study is to assess the safety and benefits of the investigational study drug, KW-2478, when given with bortezomib (Velcade®), a drug approved for the treatment of Multiple Myeloma (MM).
- Trial name
- NCT01063907
- Testing
- KW-2478, Bortezomib
- Where
- 26 sites in United States, Philippines and 1 more
- Volunteers
- 95 people
- Sponsor
- Kyowa Kirin Co., Ltd.
Psoriasis, Skin Diseases
A Phase 2b Study of Baricitinib in Participants With Moderate to Severe Psoriasis
This is a dose-ranging study designed to investigate the efficacy and safety of Baricitinib in the treatment of participants with moderate to severe, chronic plaque psoriasis as assessed by the Psoriasis Area and Severity Index…
- Conditions
- Psoriasis, Skin Diseases, Skin Diseases, Papulosquamous
- Trial name
- NCT01490632
- Testing
- Baricitinib
- Where
- 35 sites in United States, Canada and 2 more
- Volunteers
- 271 people
- Sponsor
- Eli Lilly and Company
Graft Versus Host Disease
Expressive Writing in GVHD
Graft-versus-host-disease (GVHD) is a disease phenomenon that occurs when immune cells of the donor recognize and attack healthy tissue within the transplant recipient, or host.
- Trial name
- EXPRESS-C-GVHD (NCT05694832)
- Testing
- Expressive Writing
- Where
- United States
- Volunteers
- 3 people
- Sponsor
- Northwestern University
Graft Versus Host Disease, GVHD
A Study of Itolizumab in Combination With Corticosteroids for the First-Line Treatment of Acute Graft Versus Host Disease (EQUATOR)
This is a multi-center study to compare the efficacy and safety of itolizumab versus placebo as first-line therapy for subjects with Grade III-IV aGVHD or Grade II with LGI involvement, in combination with corticosteroids
- Conditions
- Graft Versus Host Disease, GVHD, Acute-graft-versus-host Disease, Acute GVHD
- Trial name
- NCT05263999
- Testing
- Itolizumab
- Where
- 118 sites in United States, Australia and 10 more
- Volunteers
- 158 people
- Sponsor
- Equillium
Atopic Keratoconjunctivitis
An Efficacy and Safety Study of DFL24498 in the Treatment of AKC
This is a phase 3, multicenter, randomized, double-masked, parallel-group, vehicle-controlled study to evaluate the safety and efficacy of DFL24498 compared with vehicle ophthalmic solution, in participants with AKC.
- Trial name
- NCT07395232
- Testing
- DFL24498, Vehicle, dexamethasone sodium phosphate (DSP) ophthalmic solution
- Where
- 19 sites in United States, Italy and 1 more
- Volunteers
- 153 people
- Sponsor
- Dompé Farmaceutici S.p.A
Anemia, Kidney Disease, Chronic
A Retrospective Observational Study of Hemoglobin Levels in Patients With Renal Anemia Treated With Mircera (Methoxy Polyethylene Glycol-Epoetin Beta)
This retrospective observational study will evaluate the hemoglobin levels in patients with renal anemia over 6 months treatment with Mircera (methoxy polyethylene glycol-epoetin beta).
- Trial name
- NCT01379963
- Where
- 17 sites in Greece
- Volunteers
- 780 people
- Sponsor
- Hoffmann-La Roche
Psoriasis, Plaque Psoriasis
Study to Evaluate Safety and Efficacy of Oral MP1032 in Psoriasis Patients
This Phase IIa study is designed to assess the safety, tolerability and pharmacokinetics of oral MP1032 in patients with moderate to severe psoriasis over a period of 6 weeks.
- Trial name
- NCT02908347
- Testing
- MP1032
- Where
- 4 sites in Germany
- Volunteers
- 46 people
- Sponsor
- MetrioPharm AG
Chronic Graft-versus-host-disease
Efficacy and Safety of SCM-CGH in Patients With Steroid-Refractory or Dependent Chronic Graft-Versus-Host Disease
The purpose of this study is to evaluate efficacy of SCM-CGH in participants with steroid dependent/refractory chronic graft versus host disease (cGVHD) by measuring overall cGVHD response (complete response [CR] and partial…
- Trial name
- NCT04189432
- Testing
- SCM-CGH
- Where
- 11 sites in South Korea
- Volunteers
- 84 people
- Sponsor
- SCM Lifescience Co., LTD.
Chronic Spontaneous Urticaria
Dose-finding Study of QGE031 as add-on Therapy to Evaluate Efficacy and Safety in Patients With CSU
This is a placebo and active-controlled phase 2b dose-finding study to evaluate efficacy and safety of QGE031 monthly subcutaneous injections as add-on therapy in patients with Chronic Spontaneous Urticaria.
- Trial name
- NCT02477332
- Testing
- QGE031, Omalizumab
- Where
- 82 sites in United States, Australia and 8 more
- Volunteers
- 382 people
- Sponsor
- Novartis Pharmaceuticals
Acute Graft Versus Host Disease
Combination of Steroid and Humanized CD25 Monoclonal Antibody as First-line Therapy for aGVHD
The first-line treatment of acute graft-versus-host disease with humanized CD25 monoclonal antibody combined with glucocorticoid was used to study the remission rate of acute graft-versus-host disease, the cumulative incidence…
- Trial name
- NCT06473909
- Testing
- CD25 antibody combined glucocorticoid as first-line treatment
- Volunteers
- 20 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Chronic Hepatitis C
A Study of Albuferon With Ribavirin in Interferon Alfa Naive Subjects With Chronic Hepatitis C Genotype 2 or 3
A Study of Albuferon with Ribavirin in Interferon Alfa Naive Subjects with Chronic Hepatitis C Genotype 2 or 3.
- Trial name
- NCT00656006
- Testing
- Albuferon, Ribavirin
- Where
- 6 sites in Canada
- Volunteers
- 43 people
- Sponsor
- Human Genome Sciences Inc.
aGVHD
A Clinical Study on the Efficacy and Safety of Ivarmacitinib in Preventing aGVHD After HLA-matched Transplantation
To apply Ivarmacitinib for the prevention of acute graft-versus-host disease (aGVHD) in HLA haploidentical transplantation, the incidence of grade II-IV aGVHD after prevention, the incidence of primary graft failure, the rate of…
- Trial name
- Ivarmacitinib (NCT07381114)
- Testing
- Ivarmacitinib
- Volunteers
- 32 people
- Sponsor
- Institute of Hematology & Blood Diseases Hospital, China
Graft-Versus-Host Disease
Feasibility Study of Collecting Multicenter Chronic GVHD Data
Primary Objective: 1. To determine the feasibility of conducting a multi-site longitudinal observational study of patients with chronic graft-versus-host disease (GVHD).
- Trial name
- NCT00506233
- Testing
- Questionnaire
- Where
- 2 sites in United States
- Volunteers
- 13 people
- Sponsor
- M.D. Anderson Cancer Center
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.